BAT and PMI Collaborate to Produce Cigarettes in Switzerland

BATPMI by 2FIRSTS.ai
Dec.04.2023
BAT and PMI Collaborate to Produce Cigarettes in Switzerland
Swiss media Le Temps reports that British American Tobacco's Swiss subsidiary has reached a production agreement with Philip Morris International.

Swiss media outlet Le Temps reported on December 1st that the Swiss subsidiary of British American Tobacco (BAT) has revealed a collaboration agreement with Philip Morris International (PMI). According to the agreement, PMI will produce cigarettes for BAT at their factory located in the western Swiss city of Neuchâtel.

 

In its statement, BAT pointed out that this agreement is specifically targeted towards the domestic market in Switzerland. Reports suggest that due to insufficient production capacity at BAT's factories in Switzerland to meet market demands, the company has opted to collaborate with a rival factory. This is a common practice in the world of multinational corporations.

 

British American Tobacco (BAT) has announced that only a portion of its production in Neuchâtel will be dedicated to the Swiss market, while the remaining output, as well as previously exported goods, will be handled by other factories within the BAT Group. As part of the agreement between the two tobacco giants, six new positions will be added to the Boncourt factory (BAT's Switzerland-based facility).

 

This summer, British American Tobacco Switzerland announced that they would not completely exit Boncourt's operations, but would continue to retain warehouses and a shipping department there, providing approximately 15 jobs. The company's headquarters will also remain in Jura canton. As of December 14th, 2022, when the closure of the factory was announced, it employed a total of 220 staff members.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

KT&G Unveils lil hybrid 3.0 Misty Rose Limited Edition, Limited to 20,000 Devices
KT&G Unveils lil hybrid 3.0 Misty Rose Limited Edition, Limited to 20,000 Devices
KT&G has launched the limited-edition “lil hybrid 3.0 Misty Rose Edition” heated tobacco device in South Korea, betting on year-end consumer demand with a gradient rose-colored design. The release is capped at 20,000 units and is available through both online and offline channels, with an official retail price of 78,000 won (approximately USD 53).
Nov.20 by 2FIRSTS.ai
BAT Podcast with AACS CEO: Vape Policy Imbalance Fuels Australia’s Billion-Dollar Illicit Market
BAT Podcast with AACS CEO: Vape Policy Imbalance Fuels Australia’s Billion-Dollar Illicit Market
In BAT’s The Smokeless Word podcast, AACS CEO Theo Foukkare warned that high taxes and strict vape bans have fueled Australia’s AUD 10-billion illicit nicotine market and rising retail crime, urging urgent regulatory reform.
Oct.27 by 2FIRSTS.ai
COP11 Update: Deep Divide Over Regulation of E-cigarettes and Nicotine Pouches as EU Pushes Back Against "Total Ban" Draft
COP11 Update: Deep Divide Over Regulation of E-cigarettes and Nicotine Pouches as EU Pushes Back Against "Total Ban" Draft
At the ongoing COP11 in Geneva,a bloc led by Brazil and the Maldives has submitted a draft proposing "prohibition" as the primary policy path. In response, the European Union has submitted amendments requesting that the wording be adjusted to optional regulation, preserving the right of member states to decide on sales bans based on their own national laws.
Nov.21 by 2FIRSTS.ai
Lithuanian Schools Install Vape Detectors as Teen Vaping Surges
Lithuanian Schools Install Vape Detectors as Teen Vaping Surges
Over 30 Lithuanian schools have installed smart vape detectors to curb rising teen e-cigarette use. WHO data show Lithuania ranks worst among 44 countries, with 60% of 15-year-olds having tried vaping. The system alerts staff to smoke and noise changes, helping schools reduce on-campus vaping cases.
Oct.27 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Thai Cabinet Approves NHRC Proposal to Tighten E-Cigarette Regulation
Thai Cabinet Approves NHRC Proposal to Tighten E-Cigarette Regulation
Thailand’s Cabinet approved a National Human Rights Commission proposal to tighten e-cigarette regulation. The Health Ministry was instructed to raise public awareness on vaping risks and amend the 2017 Tobacco Control Act to cover all tobacco products, including vapes and new forms, while enforcing WHO FCTC Article 5.3 to prevent industry interference.
Oct.28 by 2FIRSTS.ai